These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 26788583)

  • 41. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The transparency commission: evaluation and re-evaluation].
    Bergmann JF
    Presse Med; 2001 May 26-Jun 2; 30(19):941-6. PubMed ID: 11433724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry.
    Revicki DA; Luce BR
    Psychopharmacol Bull; 1995; 31(1):57-65. PubMed ID: 7675990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New drugs and indications in 2012. Sluggish progress, timid measures to protect patients.
    Prescrire Int; 2013 Apr; 22(137):105-7. PubMed ID: 23662323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Contracts including performance and management of uncertainty].
    Duru G; Garassus P; Auray JP
    Ann Pharm Fr; 2013 Sep; 71(5):338-45. PubMed ID: 24075704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Application of pharmacoeconomics to formulary decision making in managed care organizations.
    Suh DC; Okpara IR; Agnese WB; Toscani M
    Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Analysis of generic drug supply in France].
    Taboulet F; Haramburu F; Latry P
    Rev Epidemiol Sante Publique; 2003 Sep; 51(4):415-25. PubMed ID: 13679734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Paying the piper for pharmacoeconomic studies.
    Neumann PJ
    Med Decis Making; 1998; 18(2 Suppl):S23-6. PubMed ID: 9566464
    [No Abstract]   [Full Text] [Related]  

  • 50. The rationale of pharmacoeconomic analysis in rheumatologic indications.
    Turchetti G; Scalone L; Della Casa Alberighi O; Mosca M; Montella S; Cortesi PA; Mantovani LG
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S64-71. PubMed ID: 23072796
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The development of a value based pricing index for new drugs in metastatic colorectal cancer.
    Dranitsaris G; Truter I; Lubbe MS
    Eur J Cancer; 2011 Jun; 47(9):1299-304. PubMed ID: 21493060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Economical evaluation of drugs. A steering method for the pharmaceutical sector of the 1990's?].
    Grund J; Husbyn H
    Tidsskr Nor Laegeforen; 1994 Mar; 114(8):947-50. PubMed ID: 8191475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prescrire's Médicaments en Questions: First results of a practice improvement programme.
    Prescrire Int; 2016 Dec; 25(177):305-306. PubMed ID: 30758929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The French National Medicines Assessment Committee, innovation and therapeutic progress].
    Bouvenot G
    Therapie; 2006; 61(1):13-6. PubMed ID: 16792149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is health-related quality of life sufficiently addressed in trials for breast cancer treatments? An assessment based on reimbursement opinions from the French health technology assessment body, 2009-2023.
    Kyheng M; Tonoli H; Supah N; Riou França L; Massol J
    J Cancer Policy; 2024 Sep; 42():100504. PubMed ID: 39260453
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Provenance and Clinical Benefit of Medicines Introduced to the French Market, 2008 to 2018.
    Osipenko L; Potey P; Perez B; Kupryjanczuk A; Angelov F; Schuster A; Mossialos E
    JAMA Intern Med; 2024 Jan; 184(1):46-52. PubMed ID: 37983026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Assessment of new drugs by health Authorities in France: are biomarkers really involved ?].
    Gilles G
    Rev Prat; 2021 May; 71(5):487-491. PubMed ID: 34553525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical added value of drugs: An empirical survey of French transparency committee opinions.
    Detournay B; Borel T; Trancart M; Emery C; Coudray-Omnès C;
    Therapie; 2021; 76(6):639-645. PubMed ID: 30470477
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lifestyle drugs: determining their value and who should pay.
    Mitrany D
    Pharmacoeconomics; 2001; 19(5 Pt 1):441-8. PubMed ID: 11465305
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Do newer drugs treat fewer diseases, controlling for time since launch? Evidence from France and the U.S.
    Lichtenberg FR
    J Pharm Policy Pract; 2024; 17(1):2357604. PubMed ID: 38903694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.